TASLY PHARMACEUTICAL GROUP CO.,LTD. — Investor Relations & Filings
Tasly Pharmaceutical Group Co., Ltd. specializes in the research, development, and production of modern Traditional Chinese Medicine (TCM), biological products, and chemical pharmaceuticals. The company is primarily known for its flagship cardiovascular treatment, Compound Danshen Dripping Pills, which represents a significant advancement in the modernization and standardization of herbal medicine. Its therapeutic portfolio covers cardiovascular, cerebrovascular, digestive, and metabolic diseases, as well as oncology. Tasly utilizes high-tech manufacturing processes and maintains a strong focus on R&D to bridge traditional therapies with modern clinical standards. The organization also explores digital health solutions and innovative drug delivery systems to enhance its comprehensive healthcare offerings.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 天士力第九届董事会第18次会议决议公告 | 2026-03-19 | Chinese | |
| 天士力关于对在任独立董事独立性评估的专项意见 | 2026-03-19 | Chinese | |
| 天士力2025年年度报告 | 2026-03-19 | Chinese | |
| 天士力2025年度独立董事述职报告（段亚林） | 2026-03-19 | Chinese | |
| 天士力2025年度利润分配预案的公告 | 2026-03-19 | Chinese | |
| 天士力2025年度非经营性资金占用及其他关联资金往来情况的专项说明 | 2026-03-19 | Chinese |
Browse filings by year
25 years- 2026 19 filings
- 2025 154 filings
- 2024 86 filings
- 2023 80 filings
- 2022 92 filings
- 2021 108 filings
- 2020 198 filings
- 2019 96 filings
- 2018 117 filings
- 2017 99 filings
- 2016 93 filings
- 2015 102 filings
- 2014 118 filings
- 2013 79 filings
- 2012 65 filings
- 2011 61 filings
- 2010 41 filings
- 2009 33 filings
- 2008 46 filings
- 2007 38 filings
- 2006 37 filings
- 2005 49 filings
- 2004 44 filings
- 2003 23 filings
- 2002 10 filings
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 41104895 | 天士力第九届董事会第18次会议决议公告 | 2026-03-19 | Chinese | ||
| 41104884 | 天士力关于对在任独立董事独立性评估的专项意见 | 2026-03-19 | Chinese | ||
| 41104883 | 天士力2025年年度报告 | 2026-03-19 | Chinese | ||
| 41104878 | 天士力2025年度独立董事述职报告（段亚林） | 2026-03-19 | Chinese | ||
| 41104869 | 天士力2025年度利润分配预案的公告 | 2026-03-19 | Chinese | ||
| 41104859 | 天士力2025年度非经营性资金占用及其他关联资金往来情况的专项说明 | 2026-03-19 | Chinese | ||
| 41104832 | 天士力2025年年度报告摘要 | 2026-03-19 | Chinese | ||
| 41104827 | 天士力关于签署合作协议暨关联交易的公告 | 2026-03-19 | Chinese | ||
| 41104825 | 天士力关于2025年度计提各项资产减值准备的公告 | 2026-03-19 | Chinese | ||
| 41104815 | 天士力2025年度独立董事述职报告（韩秀桃） | 2026-03-19 | Chinese | ||
| 41104801 | 天士力2025年度会计师事务所履职情况评估报告 | 2026-03-19 | Chinese | ||
| 41104797 | 天士力关于公司2025年年报主要经营数据的公告 | 2026-03-19 | Chinese | ||
| 41104782 | 天士力2025年度审计报告 | 2026-03-19 | Chinese | ||
| 41104690 | 天士力2025年可持续发展暨ESG报告 | 2026-03-19 | Chinese | ||
| 41104670 | 天士力2025年度内部控制评价报告 | 2026-03-19 | Chinese | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
13260917 Canada Inc.
Biotech developing oral small molecules to restore muscle s…
|
MSCL | CA | Manufacturing |
|
1608557 Ontario Inc.
Biopharmaceutical company dedicated to R&D, discovery, and …
|
OTROQ | CA | Manufacturing |
|
3B BlackBio Dx Limited
Develops molecular diagnostic kits for oncology, infectious…
|
3BBLACKBIO | IN | Manufacturing |
|
3D Medicines Inc.
Commercial-stage biopharma specializing in next-generation …
|
1244 | HK | Manufacturing |
|
3SBio Inc.
Biopharmaceutical enterprise specializing in R&D, productio…
|
1530 | KY | Manufacturing |
|
4BASEBIO PLC
Manufactures GMP-grade synthetic DNA for next-generation th…
|
4BB | GB | Manufacturing |
|
4D Molecular Therapeutics, Inc.
Develops genetic medicines using AAV vectors for ophthalmol…
|
FDMT | US | Manufacturing |
|
4Front Ventures Corp.
Vertically integrated cannabis operator managing cultivatio…
|
FFNT | CA | Manufacturing |
|
4SC AG
Biopharmaceutical company with no products under developmen…
|
VSC | DE | Manufacturing |
|
60 DEGREES PHARMACEUTICALS, INC.
Develops and commercializes medicines for infectious diseas…
|
SXTP | US | Manufacturing |
TASLY PHARMACEUTICAL GROUP CO.,LTD. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/56798/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=56798 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=56798 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=56798 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 56798}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for TASLY PHARMACEUTICAL GROUP CO.,LTD. (id: 56798)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.